Quantcast

Adalvo waiting EC’s marketing authorization for Livogiva

Pharmaceutical company Adalvo today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for Livogiva, indicated for use in postmenopausal women with osteoporosis who are at high risk of having bone fractures.

Read more

Eli Lilly with promising oncology presentations at ESMO

Eli Lilly on Sunday presented data from results of testing its two oncology products; for registration of oral selpercatinib monotherapy, for the treatment of RET-altered thyroid cancers, and its abemaciclib branded Verzenio in combination with fulvestrant significantly extended life by a median of 9.4 months in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer

Read more

Lilly soon seeks regulatory approval for RET fusion-positive NSCLC treatment

Eli Lilly’s test of oral selpercatinib monotherapy for the treatment of RET fusion-positive non-small cell lung cancer (NSCLC) saw a 68 percent objective response rate (ORR), and also showed that safety analysis of all 531 patients enrolled to LIBRETTO-001, selpercatinib was well-tolerated, with only 9 patients (1.7%) discontinuing therapy due to treatment-related toxicity.

Read more